专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006057531A1 LIGHT EMITTING MAT FOR VEHICLES 审中-公开
标题翻译：车辆发光灯
公开(公告)号：WO2006057531A1
公开(公告)日：2006-06-01
申请号：PCT/KR2005/004006
申请日：2005-11-26
申请人： KIM, Sean , SHIN, Hee Kwan , KIM, Eun Suk , SHIN, Hee Jong
发明人： KIM, Eun Suk , SHIN, Hee Jong
IPC分类号： B60N3/04
CPC分类号： B60N3/048 , B60Q3/20 , B60Q3/54 , B60Q3/745 , B60Q2500/10
摘要： The present invention relates to a light -emitting mat for vehicles in which a plurality of light -emitting diodes or an electro- luminescent sheet having a predetermined size is installed on an edge or a bottom of a transparent decoration plate having predetermined decorative patterns, so that the decorative patterns shine with a variety of colors as light emitted from a light -emit ting source is radiated thereto when electric power is supplied to the light-emitting diodes or an electro- luminescent sheet. An object of the present invention is to provide a light -emit ting mat for vehicles that can meet a user's desire for beauty and a variety of functions. The light-emitting mat is made of a transparent plastic material, instead of an opaque material with dark and dull colors, which are typical for conventional mats for vehicles, and has predetermined decorative patterns that shine with a variety of colors using a plurality of light -emitting diodes or an electro- luminescent sheet. Accordingly, decorative effect of the mat according to the present invention is highly improved.
摘要翻译：本发明涉及一种用于车辆的发光垫，其中多个发光二极管或具有预定尺寸的电致发光片安装在具有预定装饰图案的透明装饰板的边缘或底部上，因此，当向发光二极管或电致发光片提供电力时，装饰图案以各种颜色发光，当从光源发出的光被照射到其上。本发明的目的是提供一种能够满足用户对美容和各种功能的渴望的用于车辆的光照射垫。发光垫由透明塑料材料制成，而不是具有暗色和暗色的不透明材料，这是典型的用于车辆的常规垫片，并且具有预定的装饰图案，其使用多种光线以各种颜色照射发光二极管或电致发光片。因此，根据本发明的垫的装饰效果大大提高。

2. 发明申请

WO2006033505A1 PAROXETINE CHOLATE OR CHOLIC ACID DERIVATIVE SALTS, AND COMPOSITION COMPRISING PAROXETINE AND CHOLIC ACID OF CHOLIC ACID DERIVATIVES 审中-公开
标题翻译：异黄酮或胆酸衍生物，以及包含胆酸和胆酸的化合物的组合物
公开(公告)号：WO2006033505A1
公开(公告)日：2006-03-30
申请号：PCT/KR2004/003477
申请日：2004-12-28
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , LEE, Sang Joon , SHIN, Hee Jong , KI, Min Hyo , LEE, Su Kyoung , KIM, Bok Young , LEE, Hong Woo
发明人： LEE, Sang Joon , SHIN, Hee Jong , KI, Min Hyo , LEE, Su Kyoung , KIM, Bok Young , LEE, Hong Woo
IPC分类号： C07D405/12
CPC分类号： C07D405/12 , C07J43/00
摘要： Disclosed herein is a paroxetine cholate or cholic acid derivative salt and a composition comprising paroxetine and cholic acid or a derivative thereof. Further disclosed is a pharmaceutical composition comprising the paroxetine salt or the composition. The pharmaceutical composition can be formulated into an oral preparation for swallowing without water as an orally disintegrating tablet for paroxetine.
摘要翻译：本文公开了帕罗西汀胆酸盐或胆酸衍生物盐和包含帕罗西汀和胆酸或其衍生物的组合物。还公开了包含帕罗西汀盐或组合物的药物组合物。作为帕罗西汀的口腔崩解片剂，可以将药物组合物配制成无水的口服制剂。

3. 发明申请

WO2005067926A1 PHARMACEUTICAL COMPOSITION OF AMLODIPINE MALEATE HAVING ENHANCED STABILITY 审中-公开
标题翻译：具有增强稳定性的阿米膦酸马来酸的药物组合物
公开(公告)号：WO2005067926A1
公开(公告)日：2005-07-28
申请号：PCT/KR2005/000120
申请日：2005-01-14
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , LEE, Sang-Joon , SHIN, Hee-Jong , LIM, Jong-Lae , LEE, Seok-Kyu , MOON, Soo-Yeon , PARK, Shin-Jung , SHIN, Taek-Hwan
发明人： LEE, Sang-Joon , SHIN, Hee-Jong , LIM, Jong-Lae , LEE, Seok-Kyu , MOON, Soo-Yeon , PARK, Shin-Jung , SHIN, Taek-Hwan
IPC分类号： A61K31/4422
CPC分类号： A61K9/5015 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2077 , A61K9/2081 , A61K9/5026 , A61K9/5047 , A61K31/4422
摘要： The present invention relates to a coated particle of amlodipine maleate and a pharmaceutical composition for cardiovascular disease (CVD) comprising the coated particle of amlodipine maleate. The pharmaceutical composition of the present invention has stable bioavailability due to sufficient dissolution rate and prevents decomposition reaction of amlodipine to thereby being formulated with formulation-stability equal to or higher than amlodipine besylate under long storage.
摘要翻译：本发明涉及马来酸氨氯地平的包衣颗粒和包含马来酸氨氯地平的包衣颗粒的用于心血管疾病（CVD）的药物组合物。本发明的药物组合物由于足够的溶解速率而具有稳定的生物利用度，并且防止了氨氯地平的分解反应，从而在长期储存下配制成等于或高于苯磺酸氨氯地平的制剂稳定性。

4. 发明申请

WO0145484A3 AN IMPROVED PROCESS FOR PREPARING SIMVASTATIN 审中-公开
标题翻译：制备SIMVASTATIN的改进方法
公开(公告)号：WO0145484A3
公开(公告)日：2002-03-28
申请号：PCT/KR0100301
申请日：2001-02-27
申请人： CHONG KUN DANG PHARM CORP , HONG CHUNG IL , KIM JUNG WOO , SHIN HEE JONG , KANG TAE WON , CHO DONG OCK
发明人： HONG CHUNG IL , KIM JUNG WOO , SHIN HEE JONG , KANG TAE WON , CHO DONG OCK
IPC分类号： A44C5/00 , A61K31/366 , A61P3/06 , A61P43/00 , C07B53/00 , C07D309/30
CPC分类号： C07D309/30 , Y02P20/55
摘要： The present invention relates to an improved process for preparing simvastatin and more particularly, the improved process for preparing simvastatin expressed by formula 1 with high yield and high purity by performing the following sequential processes comprising: (i) hydrolysis of lovastatin as starting material with potassium t-butoxide in an organic solvent and small amount of water under a mild reaction condition, followed by lactonization of the obtained solid intermediate with preventing from formation of by-products; (ii) protection of an alcohol group with t-butyldimethylsilyl group which can be easily removed with concentrated hydrochloric acid without the formation of by-products; (iii) acylation of the obtained protected intermediate with acyloxytriphenyl phosphonium salt as an acylating agent under a mild reaction condition; and (iv) removal of the silyl protective group with a concentrated hydrochloric acid. The present invention is to provide the improved process of preparing simvastatin expressed by formula 1 environmentally sound, economically efficient, and industrially useful.
摘要翻译：本发明涉及一种制备辛伐他汀的改进方法，更具体地说，涉及通过进行以下顺序方法制备具有高产率和高纯度的式1所表达的辛伐他汀的改进方法，包括：（i）将洛伐他汀作为原料与钾叔丁醇在有机溶剂和少量水中，在温和的反应条件下，然后将所得固体中间体内酯化，防止副产物的形成; （ii）用叔丁基二甲基甲硅烷基保护醇基，其可以用浓盐酸容易地除去而不形成副产物; （iii）在温和的反应条件下用酰氧基三苯基鏻盐作为酰化剂酰化所得保护的中间体; 和（iv）用浓盐酸除去甲硅烷基保护基。本发明提供了由式1表达的辛伐他汀的改进方法，其在环境无害，经济有效和工业上有用。

5. 发明申请

WO1995022982A1 CYCLOSPORIN-CONTAINING POWDER COMPOSITION 审中-公开
标题翻译：含有CYPOSPORIN的粉末组合物
公开(公告)号：WO1995022982A1
公开(公告)日：1995-08-31
申请号：PCT/KR1994000125
申请日：1994-09-16
申请人： CHONG KUN DANG CORP. , KIM, Jung, Woo , SHIN, Hee, Jong , PARK, Joon, Kyu , MIN, Kyeong, Bok
发明人： CHONG KUN DANG CORP.
IPC分类号： A61K38/08
CPC分类号： A61K38/13 , A61K9/143 , A61K9/145 , A61K9/1623 , A61K9/485 , A61K9/4858 , Y10S514/97
摘要： The present invention relates to a cyclosporin-containing powder composition which comprises cyclosporin, a non-ionic hydrophilic surfactant and a porous carrier. In addition, the present invention relates to a method for preparing the cyclosporin-containing powder composition which comprises dissolving cyclosporin and a non-ionic hydrophilic surfactant in an organic solvent, adding a porous carrier to the resulting solution and then evaporating the organic solvent from the mixture. The powder composition of the present invention is stable and does not require a special manufacturing technique when it is formulated. In addition, since the powder composition of the present invention does not contain an organic solvent, the necessity of a special package is excluded. Furthermore, the composition of the present invention provides an improved bioavailability which results in decrease of a single dosage, and therefore, can contribute to the alleviation of the side effects associated with cyclosporin.
摘要翻译：本发明涉及含环孢菌素的粉末组合物，其包含环孢菌素，非离子亲水性表面活性剂和多孔载体。另外，本发明涉及一种制备含有环孢菌素的粉末组合物的方法，该方法包括将环孢菌素和非离子亲水性表面活性剂溶解在有机溶剂中，向所得溶液中加入多孔载体，然后从混合物。本发明的粉末组合物稳定，配制时不需要特殊的制造技术。此外，由于本发明的粉末组合物不含有机溶剂，因此不需要特殊包装。此外，本发明的组合物提供改善的生物利用度，其导致单一剂量的降低，因此可有助于缓解与环孢菌素相关的副作用。

6. 发明申请

WO2012161539A3 SIRNA FOR INHIBITING THE EXPRESSION OF BHRF1 AND COMPOSITION COMPRISING SAME 审中-公开
标题翻译： SIRNA用于抑制BHRF1的表达和包含其的组合物
公开(公告)号：WO2012161539A3
公开(公告)日：2013-01-17
申请号：PCT/KR2012004135
申请日：2012-05-24
申请人： CATHOLIC UNIV IND ACAD COOP , LEE SUK-KYEONG , SHIN HEE-JONG
发明人： LEE SUK-KYEONG , SHIN HEE-JONG
IPC分类号： C12N15/113 , A61K31/7105 , A61K48/00 , A61P35/00
CPC分类号： A61K31/713 , C12N15/1131 , C12N2310/14
摘要： The present invention relates to an siRNA which inhibits the expression of BHRF1 in the Epstein-Bar virus (EBV), and to a compound for inhibiting resistance to anticancer medications using the siRNA. More particularly, the present invention relates to an siRNA which inhibits the expression of BHRF1, and to a composition for inhibiting resistance to anticancer medications for the treatment of EBV-positive stomach cancer, comprising the siRNA. Further, the present invention relates to a composition for the treatment of EBV-positive stomach cancer, comprising the siRNA and the anti-cancer agent.
摘要翻译：本发明涉及抑制EB病毒（EBV）中BHRF1表达的siRNA和使用siRNA抑制抗癌药物抗性的化合物。更具体地说，本发明涉及抑制BHRF1表达的siRNA，以及涉及用于抑制抗癌药物治疗EBV阳性胃癌抗性的组合物，其包含该siRNA。此外，本发明涉及用于治疗EBV阳性胃癌的组合物，其包含siRNA和抗癌剂。

7. 发明申请

WO2007069827A1 PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE LAYER AND FAST RELEASE LAYER FOR TREATMENT OF HYPERLIPIDEMIA AND ARTERIOSCLEROSIS 审中-公开
标题翻译：具有扩展释放层和快速释放层的药物组合物用于治疗高磷脂酰胆碱和血栓形成
公开(公告)号：WO2007069827A1
公开(公告)日：2007-06-21
申请号：PCT/KR2006/004738
申请日：2006-11-13
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee Jong , KI, Min Hyo , LEE, Jin Woo , KIM, Byoung Su
发明人： SHIN, Hee Jong , KI, Min Hyo , LEE, Jin Woo , KIM, Byoung Su
IPC分类号： A61K9/22 , A61P9/10
CPC分类号： A61K9/209
摘要： The present invention provides a pharmaceutical composition comprising a therapeutically amount of nicotinic acid and a nicotinic acid compound or mixtures thereof in a sustained release form and a therapeutically amount of a HMG-CoA reductase inhibitor in a fast release form which can optimally treat hyperlipidemia and arteriosclerosis by minimizing the interaction of two drugs. The pharmaceutical composition of the present invention comprising a coated two- layer tablet a) one sustained release layer containing nicotinic acid and a nicotinic acid compound or mixtures thereof, together with a sustained release polymer and b) another fast release layer containing a HMG-CoA reductase inhibitor, a film- or layer- forming agent, a re- crystallization inhibitor and a plasticizer, can minimize the interaction of the two drugs via controlled release profile and treat optimally hyperlipidemia and arteriosclerosis.
摘要翻译：本发明提供药物组合物，其包含治疗量的烟酸和烟酸化合物或其缓释形式的混合物和治疗量的快速释放形式的HMG-CoA还原酶抑制剂，其可以最佳地治疗高脂血症和动脉硬化通过最小化两种药物的相互作用。本发明的药物组合物包含包被的两层片剂a）一个含有烟酸和烟酸化合物或其混合物的持续释放层以及持续释放聚合物，以及b）包含HMG-CoA的另一快速释放层还原酶抑制剂，成膜剂或成层剂，再结晶抑制剂和增塑剂，可以通过控制释放曲线最小化两种药物的相互作用，并治疗最佳高脂血症和动脉硬化。

8. 发明申请

WO2006033505A8 PAROXETINE CHOLATE OR CHOLIC ACID DERIVATIVE SALTS, AND COMPOSITION COMPRISING PAROXETINE AND CHOLIC ACID OR CHOLIC ACID DERIVATIVES 审中-公开
标题翻译：异黄酮或胆酸衍生物，以及包含PAROXETINE和胆酸或胆酸衍生物的组合物
公开(公告)号：WO2006033505A8
公开(公告)日：2006-09-14
申请号：PCT/KR2004003477
申请日：2004-12-28
申请人： CHONG KUN DANG PHARM CORP , LEE SANG JOON , SHIN HEE JONG , KI MIN HYO , LEE SU KYOUNG , KIM BOK YOUNG , LEE HONG WOO
发明人： LEE SANG JOON , SHIN HEE JONG , KI MIN HYO , LEE SU KYOUNG , KIM BOK YOUNG , LEE HONG WOO
IPC分类号： C07D405/12 , A61K31/445 , A61P25/24
CPC分类号： C07D405/12 , C07J43/00
摘要： Disclosed herein is a paroxetine cholate or cholic acid derivative salt and a composition comprising paroxetine and cholic acid or a derivative thereof. Further disclosed is a pharmaceutical composition comprising the paroxetine salt or the composition. The pharmaceutical composition can be formulated into an oral preparation for swallowing without water as an orally disintegrating tablet for paroxetine.
摘要翻译：本文公开了帕罗西汀胆酸盐或胆酸衍生物盐和包含帕罗西汀和胆酸或其衍生物的组合物。还公开了包含帕罗西汀盐或组合物的药物组合物。作为帕罗西汀的口腔崩解片剂，可以将药物组合物配制成无水的口服制剂。

9. 发明申请

WO2006080780A1 PHARMACEUTICAL COMPOSITIONS CONTAINING BISPHOSPHONATE FOR IMPROVING ORAL ABSORPTION 审中-公开
标题翻译：含有二磷酸酯的药物组合物，用于改善口服吸收
公开(公告)号：WO2006080780A1
公开(公告)日：2006-08-03
申请号：PCT/KR2006/000013
申请日：2006-01-03
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa , LEE, Jin-Woo
发明人： SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa , LEE, Jin-Woo
IPC分类号： A61K31/663 , A61P19/10
CPC分类号： A61K9/2054 , A61K9/0095 , A61K9/1623 , A61K9/1652 , A61K9/2013 , A61K9/205 , A61K9/2059 , A61K31/663
摘要： Provided is a pharmaceutical composition having improved oral absorption of a bisphosphonate drug, comprising at least one active substance selected from bisphosphonate drugs having non-permeability to a lipid biomembrane due to ionization and high water-solubility in vivo and having bioavailability of less than 10%, and at least one selected from biocompatible water-soluble chitosan, as essential ingredients.
摘要翻译：本发明提供了具有改善的双膦酸盐药物口服吸收的药物组合物，其包含至少一种活性物质，所述活性物质由于离子化而对脂质生物膜具有非渗透性，并且在体内具有高水溶性，并且具有小于10％的生物利用度，，和选自生物相容性水溶性壳聚糖中的至少一种作为必需成分。

10. 发明申请

WO2005123138A9 PHARMACEUTICAL PELLET COMPOSITIONS FOR CONTROLLED RELEASE 审中-公开
标题翻译：用于控制释放的药物颗粒组合物
公开(公告)号：WO2005123138A9
公开(公告)日：2006-04-06
申请号：PCT/KR2005000666
申请日：2005-03-10
申请人： CHONG KUN DANG PHARM CORP , LEE SANG-JOON , SHIN HEE-JONG , KI MIN-HYO , YOON BOK-YOUNG
发明人： LEE SANG-JOON , SHIN HEE-JONG , KI MIN-HYO , YOON BOK-YOUNG
IPC分类号： A61K9/22 , A61K9/16 , A61K47/30
CPC分类号： A61K9/1635 , A61K9/1617 , A61K9/1652
摘要： The present invention provides a pharmaceutical composition in the form of pellet wherein controlled release of pharmacologically active substances can be effected. The present invention is characterized by a pharmaceutical composition for controlled release pellets, consisting es¬ sentially of: a) one or more pharmacologically active substances; b) one or more lipids having a low-melting point of less than 70°C and existing as a solid at room temperature; c) one or more hydrophilic substances; and d) one or more water-insoluble binding agents, prepared without melting the lipids.
摘要翻译：本发明提供了丸剂形式的药物组合物，其中可以实现药理活性物质的控制释放。本发明的特征在于用于控释丸剂的药物组合物，其包括：a）一种或多种药理活性物质; b）一种或多种低熔点小于70℃并在室温下作为固体存在的脂质; c）一种或多种亲水性物质; 和d）一种或多种不溶于脂质的水不溶性结合剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式